MBRX +61% on preclinical purported cancer breakthrough: https://finance.yahoo.com/news/moleculin-announces-breakthrough-discovery-molecule-133000609.html Even after today’s pop, the stock is down more than 50% from its mid-2016 IPO. Caveat emptor.